Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,794 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neurologic Autoimmune Disease Clear all
Completed No phase listed Observational

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

NCT06668324
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 5, 2026, 6:11 AM EDT
Recruiting Not applicable Interventional

Central Vein Sign in Multiple Sclerosis Extension Study

NCT07424027
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI Contrast
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

NCT03621761
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Telephone-based Cognitive Behavioral Therapy, Modafinil
Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 5, 2026, 6:11 AM EDT
Completed No phase listed Observational

JC-Virus (JCV) Antibody Program

NCT01070823
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri® (natalizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Not applicable Interventional

Promoting Physical Activity for Persons With Multiple Sclerosis

NCT00513448
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Group wellness intervention, Individualized physical rehabilitation
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 8, 2007 · Synced Oct 5, 2026, 6:11 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

NCT01623076
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Optic Neuritis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 5, 2026, 6:11 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490
View directory record Official record
Conditions
Multiple Sclerosis Spasticity
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 6:11 AM EDT
Recruiting Phase 2 Interventional

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

NCT06463743
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
metformin, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
55 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 5, 2026, 6:11 AM EDT
Completed No phase listed Observational

TYSABRI Global Observational Program in Safety

NCT00477113
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
2,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 5, 2026, 6:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)

NCT03710278
View directory record Official record
Conditions
Meningitis, Encephalitis, Guillain-Barré, Subarachnoid Hemorrhage, Intracranial Neoplasm, Intracranial CNS Disorder
Interventions
LPat Device
Device
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

NCT02421276
View directory record Official record
Conditions
Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
Interventions
Phlebotomy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 5, 2026, 6:11 AM EDT
Completed No phase listed Observational

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

NCT04855617
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Wellesley, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 5, 2026, 6:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

NCT02038049
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Long Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Not applicable Interventional

Clinical Trial of a Serious Game for Individuals With SCI/D

NCT02341950
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Involvement, Spina Bifida, Transverse Myelitis, Polio and Post-polio Syndrome, Syringomyelia, Spinal Stenosis, Spinal Neoplasms, Spinal Cord Diseases
Interventions
SCI Hard
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 29 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Results available

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

NCT03961204
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Data Collection
Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Results available

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

NCT01895335
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
75
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Not applicable Interventional

Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis

NCT03345199
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Inspiratory Muscle Trainer (IMT)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 5, 2026, 6:11 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 5, 2026, 6:11 AM EDT
Recruiting Not applicable Interventional

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 1 Interventional

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

NCT00017628
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
cyclophosphamide, filgrastim, methylprednisolone, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Northwestern Memorial Hospital
Other
Eligibility
0 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 6:11 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chronic Pain, Couples, & Physical Activity

NCT04077164
View directory record Official record
Conditions
Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
Interventions
No intervention, observational only.
Other
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 2Phase 3 Interventional

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

NCT00223301
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (cellcept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 5, 2026, 6:11 AM EDT
Completed Phase 3 Interventional Results available

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
52
States / cities
Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 5, 2026, 6:11 AM EDT